Anaemia in pregnancy linked to 47 per cent higher risk of heart condition in child at birth: UK Study
congenital heart disease
- in which one has heart defects at birth affecting the organ's function.
"We already know that the risk of congenital heart disease can be raised by a variety of factors, but these results develop our understanding of anaemia. Knowing that early maternal anaemia is so damaging could be a game changer worldwide," corresponding author Duncan B. Sparrow, from the
University of Oxford
, UK, said.
In this study, published in the British Journal of Obstetrics and Gynaecology, the researchers analysed health records of women who became pregnant between January 1998 and October 2020.
Over 2,700 women participants had a child diagnosed with a heart problem at birth, while 13,880 women did not. Haemoglobin levels are measured in the first 100 days of pregnancy, according to the country's National Institute for Health and Care Excellence guidelines.
More than 120 children with congenital heart disease and 390 children with normal heart function were found to have had anaemia.
"This is the first study in a UK population that demonstrates an association between maternal anaemia in early pregnancy and CHD (congenital heart disease) in offspring, demonstrating a 47 per cent higher odds of CHD in the child," the authors wrote.
In a 2021 study published in Nature Communications journal, the researchers had identified anaemia in pregnant mice as a risk factor for causing heart defects in offspring mice, which was "previously unknown".
The team said that the effects of anaemia in mid-to-late pregnancy on the foetus's development are well understood and include a low weight of the child at birth.
However, evidence on the link between
anaemia in pregnancy
and congenital heart disease in children is "mixed and weak", they said.
In this study, the team looked at the link between anaemia in early pregnancy and the risk of the child being born with a heart condition.
"Because iron deficiency is the root cause of many cases of anaemia, widespread iron supplementation for women - both when trying for a baby and when pregnant - could help prevent congenital heart disease in many newborns before it has developed," Sparrow said.
The health records analysed were taken from the UK Clinical Practice Research Datalink GOLD database.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 days ago
- Time of India
Weight loss before IVF may improve odds of pregnancy
London: Women seeking in vitro fertilization might improve their odds of becoming pregnant if they lose weight, but the magnitude of any advantage wasn't clear, in a new analysis of previous studies. The benefit of weight loss was mainly seen in the few couples who ultimately achieved pregnancy without assistance, however. While weight loss interventions appeared to improve the likelihood of spontaneous pregnancy - negating the need for IVF - it was not clear whether they improved the odds of IVF-induced pregnancy, according to the report by lead researcher Moscho Michalopoulou and colleagues at the University of Oxford in the Annals of Internal Medicine. Also unclear was whether weight loss improved the odds of a live birth. Weight loss interventions studied included low-calorie diets, an exercise program accompanied by healthy eating advice, and pharmacotherapy accompanied by diet and physical activity advice - but no single approach seemed better than another. The 12 randomized trials in the review were small, and the wide variety of methods employed by the various research teams made it hard to compare the results, the authors of the new analysis wrote. Weight loss did not appear to increase the risk of pregnancy loss, the researchers also found. Dr. Alan Penzias, an IVF specialist at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, published an editorial with the study. He notes that "weight reduction among people with overweight or obesity has many known health benefits... (and) some patients may also achieve a desired pregnancy as a consequence of weight loss." But in decision-making about IVF, the editorial continues, "we must consider the marked decrease in fertility as age increases... and other factors that weight loss cannot address." EXPERIMENTAL NANOBOTS SEAL OFF SENSITIVE TOOTH NERVES Experimental microscopic robots that travel into tiny tunnels in teeth may one day offer lasting relief from tooth sensitivity, laboratory experiments suggest. Tooth sensitivity - sharp, sudden pain triggered by hot, cold, sweet, or sour substances - occurs when the protective layers of the tooth are compromised, exposing the underlying nerve endings. The researchers' so-called CalBots are 400-nanometer magnetic particles loaded with a ceramic formula that mimics the natural environment of the tooth. Guided by an external magnetic field, the tiny bots travel deep into the exposed tubules and assemble themselves into cement-like plugs that protect the nerve. In lab experiments on extracted human teeth, high-resolution imaging confirmed that the bots had created tight seals, the researchers reported. In animal tests, they found that mice with tooth sensitivity who had been avoiding cold water would drink it again after treatment with the CalBot solution. Most current treatments for tooth sensitivity, such as desensitizing toothpastes, offer only surface-level relief and need to be reapplied regularly, while the CalBots would provide longer-lasting relief in just one application, the researchers reported in Advanced Science. They hope their treatment - which still needs to be tested in humans - might eventually offer benefits beyond the relief of dental hypersensitivity, such as minimizing the penetration of bacteria into cavities and tooth injuries. "We didn't want to create a slightly better version of what's already out there," study leader Shanmukh Peddi, a post-doctoral researcher at the Indian Institute of Science in Bangalore, said in a statement. "We wanted a technology that solves a real problem in a way that no one's attempted before." Peddi is a co-founder of Theranautilus, a Bangalore nanotechnology and healthcare company.
Time of India
12-08-2025
- Time of India
Expert panel has recommended that India doesn't fall within criteria for adopting malaria vaccines: Govt
An expert panel suggests India need not adopt malaria vaccines. These vaccines are for areas with moderate to high transmission. They are also for places with high risk of child deaths from malaria. Anupriya Patel shared this in Rajya Sabha. She responded to a question about the R21/Matrix-M vaccine. The University of Oxford and Serum Institute of India co-developed it. Tired of too many ads? Remove Ads An expert committee has recommended that India does not fall within the criteria for adopting malaria vaccines as they are used for moderate to high transmission settings with a risk of deaths in children, Rajya Sabha was informed on of State for Health Anupriya Patel was responding to a question on whether India's first malaria vaccine, R21/Matrix-M , has been co-developed by the University of Oxford and the Serum Institute of India and if the vaccine has received regulatory approval for use in the country."The matter for use of Malaria vaccine in context of India has been reviewed in a duly constituted expert committee which recommended that India does not fall within the criteria for adopting Malaria vaccines as the vaccines are used for moderate to high transmission settings with a risk of Malaria deaths in children ," she said in a written reply.
The Hindu
12-08-2025
- The Hindu
Expert panel has recommended that India doesn't fall within criteria for adopting malaria vaccines: Govt
An expert committee has recommended that India does not fall within the criteria for adopting malaria vaccines as they are used for moderate to high transmission settings with a risk of deaths in children, Rajya Sabha was informed on Tuesday (August 12, 2025). Minister of State for Health Anupriya Patel was responding to a question on whether India's first malaria vaccine, R21/Matrix-M, has been co-developed by the University of Oxford and the Serum Institute of India and if the vaccine has received regulatory approval for use in the country. "The matter for use of Malaria vaccine in context of India has been reviewed in a duly constituted expert committee which recommended that India does not fall within the criteria for adopting Malaria vaccines as the vaccines are used for moderate to high transmission settings with a risk of Malaria deaths in children," she said in a written reply.
